Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016', provides in depth analysis on Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted pipeline therapeutics. The report provides comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - The report reviews Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects - The report assesses Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table Of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) Overview 6 Therapeutics Development 7 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Products under Development by Stage of Development 7 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Products under Development by Therapy Area 8 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Products under Development by Indication 9 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Products Glance 10 Early Stage Products 10 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Products under Development by Companies 11 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Assessment 13 Assessment by Monotherapy/Combination Products 13 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 17 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development 19 La Jolla Pharmaceutical Company 19 Tolero Pharmaceuticals, Inc. 20 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Drug Profiles 21 LJPC-6417 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 TP-0184 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 TP-0413 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Dormant Projects 28 Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Featured News & Press Releases 29 Dec 07, 2015: Tolero Pharmaceuticals Presents Positive Preclinical Data on Hepcidin Inhibition for the Treatment of Anemia Associated with Chronic Disease 29 Nov 12, 2015: Tolero Pharmaceuticals Presents Positive Clinical and Preclinical Data on TP-0184 in Leukemia and Anemia at the 57th ASH Annual Meeting and Exposition 29 Aug 18, 2015: La Jolla Pharmaceutical Company Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva 30 Jun 16, 2015: Tolero Pharmaceuticals Presents Positive Preclinical Data on Hepcidin Inhibition for the Treatment of Anemia Associated with Chronic Disease 30 Jun 04, 2015: Tolero Pharmaceuticals to Present Preclinical Pipeline Data On TP-0184 at the 20th Congress of European Hematology Association, EHA 31 Apr 18, 2013: La Jolla Pharma Receives Orphan Designation From FDA For LJPC-6417 31 Sep 14, 2012: Tolero Pharma Receives Small Business Innovation Research Contract From National Cancer Institute 32 Nov 16, 2011: Hormone That Controls Iron Levels May Be Target for Atherosclerosis Treatment 32 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List Of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 13 Number of Products by Stage and Mechanism of Action, H2 2016 14 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by La Jolla Pharmaceutical Company, H2 2016 19 Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 20 Dormant Projects, H2 2016 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.